John Murphy, CEO, The COVID-19 Long haul Foundation
A mechanistic synthesis of persistent SARS-CoV-2 infection, immune dysregulation, autoimmunity, vascular dysfunction, metabolic disturbance, and host susceptibility
Summary
Post-acute sequelae of SARS-CoV-2 infection (PASC), or Long COVID, has evolved from an initially poorly characterized collection of persistent symptoms into a biologically demonstrable multisystem disorder. The central scientific problem is no longer whether patients can remain ill after apparent recovery from acute COVID-19, but rather which biological mechanisms maintain disease in particular patients, how those mechanisms interact, and why clinical phenotypes differ so markedly among individuals.
The accumulated evidence supports neither a single lesion nor a single molecular pathway. Instead, Long COVID appears to comprise partially overlapping biological endotypes generated by persistent viral material, tissue injury, chronic immune activation, impaired immune regulation, autoimmunity, endothelial and microvascular dysfunction, autonomic disturbance, metabolic and mitochondrial abnormalities, gastrointestinal and microbiome alterations, and reactivation of latent viruses.
Evidence for persistence of SARS-CoV-2 is particularly consequential. Viral RNA or protein has been detected in tissues months after acute infection, and population surveillance has identified a subset of individuals with prolonged high-titre viral RNA, whose odds of subsequently reporting Long COVID were more than 50% higher than those of individuals without persistent infection. Persistent viral material therefore provides a plausible initiating or perpetuating stimulus, although its presence does not establish that it is pathogenic in every affected patient.
At the same time, contemporary immunological studies demonstrate persistent activation of inflammatory, complement, JAK–STAT and IL-6 pathways, altered lymphocyte function, T-cell exhaustion and metabolic dysregulation more than six months after infection. Single-cell multi-omic investigations have further identified a distinct circulating monocyte state associated with fatigue, respiratory symptoms, profibrotic transcriptional programmes and impaired interferon responses.
The most defensible current model is therefore one of persistent host–virus disequilibrium. SARS-CoV-2 initiates tissue and immune perturbation; in susceptible individuals, incomplete viral clearance, latent-virus reactivation, maladaptive immunity and altered cellular physiology interact to prevent restoration of homeostasis. Clinical disease consequently becomes self-sustaining even after the acute infection has subsided.
Introduction
The conventional paradigm of viral infection assumes a relatively simple sequence:
infection → replication → immune clearance → recovery.
Long COVID challenges that model.
For a substantial minority of individuals, SARS-CoV-2 infection is followed by a prolonged period of fatigue, post-exertional malaise, cognitive dysfunction, dyspnoea, dysautonomia, pain, sleep disturbance, sensory abnormalities and multisystem physiological impairment. The illness may begin immediately after the acute infection, emerge after an apparent period of recovery, or fluctuate over months or years.
The clinical heterogeneity is striking.
One patient may primarily have orthostatic intolerance and tachycardia; another may have pulmonary impairment; another severe cognitive dysfunction and fatigue; another neuropathic pain; and another a predominantly gastrointestinal or vascular phenotype.
Such heterogeneity strongly argues against a single pathological lesion.
The more plausible interpretation is that SARS-CoV-2 functions as a trigger for several interacting biological cascades, whose relative contribution differs among individuals.
I. Etiological Architecture
Five major mechanisms currently have the strongest biological support:
- persistent SARS-CoV-2 infection or antigenic reservoirs;
- persistent immune dysregulation;
- autoimmunity and aberrant adaptive immunity;
- vascular, endothelial and coagulation abnormalities;
- cellular metabolic and autonomic dysfunction.
A sixth mechanism—reactivation of latent viruses, particularly EBV—may amplify several of these processes.
These mechanisms should not be viewed as mutually exclusive.
Indeed, they may form a causal network:
persistent viral antigen
↓
innate immune activation
↓
adaptive immune dysregulation
↓
endothelial and metabolic injury
↓
autonomic and organ dysfunction
↓
persistent symptoms.
This framework accommodates both biological persistence and clinical heterogeneity.
II. Persistent SARS-CoV-2: The Reservoir Hypothesis
One of the most consequential developments in Long-COVID research has been the accumulation of evidence that SARS-CoV-2 material can persist beyond the acute phase.
RNA, viral proteins, and—in some investigations—evidence consistent with ongoing replication have been detected in tissues including gastrointestinal, respiratory and lymphoid compartments.
The concept of a viral reservoir is mechanistically attractive.
A persistent reservoir need not generate large quantities of infectious virus.
Even low-level viral transcription or intermittent antigen release could theoretically maintain:
- innate immune activation;
- antigen presentation;
- T-cell stimulation;
- cytokine production;
- endothelial activation;
- complement activation;
- and autoimmune responses.
Thus:
persistent antigen does not require persistent systemic viraemia.
This distinction is clinically important.
A patient can have no detectable virus in peripheral blood while retaining biologically active viral material in a tissue compartment.
III. Population Evidence for Persistent Infection
Population surveillance provides epidemiological support for this model.
In a large UK surveillance study, 381 individuals had SARS-CoV-2 RNA persisting at high titre for at least 30 days, and 54 had detectable high-titre RNA for at least 60 days. Individuals with persistent infection had more than 50% higher odds of reporting Long COVID than those without persistent infection.
This is important but not definitive.
Persistence could be:
- a cause of Long COVID;
- a consequence of impaired host immunity;
- or a marker of an underlying susceptibility that independently predisposes to Long COVID.
The distinction requires intervention.
If eradication of persistent virus consistently prevents or reverses disease, causality becomes substantially more compelling.
IV. Tissue Persistence and Pathology
The pathological significance of a reservoir depends upon its anatomical location.
A reservoir in intestinal tissue could influence:
- gut permeability;
- microbiome composition;
- mucosal immunity;
- systemic cytokine production.
A reservoir in pulmonary tissue could contribute to:
- persistent inflammation;
- impaired gas exchange;
- macrophage activation;
- fibrosis.
A reservoir within vascular or endothelial compartments could theoretically influence:
- coagulation;
- endothelial activation;
- microvascular perfusion.
A reservoir involving the nervous system would have potentially profound implications for:
- cognition;
- autonomic regulation;
- sensory processing;
- fatigue.
Accordingly, the question should no longer be simply “Is SARS-CoV-2 still present?”
It should be:
Where is it present, in what cellular compartment, in what molecular form, and is it transcriptionally or translationally active?
V. Immune Dysregulation
Perhaps the most reproducible biological observation in Long COVID is persistent alteration of the immune system.
Recent longitudinal work has identified sustained activation of:
- IL-6;
- JAK–STAT;
- interferon;
- NF-κB;
- complement;
- inflammatory cytokine pathways;
together with evidence of impaired cytotoxic T-cell function and T-cell exhaustion.
These abnormalities were observed beyond 180 days after infection.
Such findings are difficult to reconcile with a purely psychological or nonspecific deconditioning model.
They indicate persistent biological alteration.
VI. The IL-6–JAK–STAT Axis
The IL-6–JAK–STAT pathway deserves particular attention.
IL-6 is a central regulator of inflammatory signalling, acute-phase responses, B-cell differentiation and T-cell biology.
Persistent activation can produce a self-reinforcing inflammatory state.
In recent multi-omic analyses, Long-COVID participants demonstrated increased IL-6 and JAK–STAT signalling together with complement and metabolic abnormalities.
This suggests a possible pathway:
persistent antigen
→ innate immune recognition
→ IL-6 production
→ JAK–STAT activation
→ transcriptional reprogramming
→ chronic inflammatory phenotype.
Whether IL-6 is a driver or merely a downstream marker remains uncertain.
VII. Complement Activation
Complement has emerged as another important component of the Long-COVID phenotype.
Complement is normally a protective component of innate immunity.
Persistent activation, however, can cause:
- endothelial injury;
- platelet activation;
- leukocyte recruitment;
- vascular permeability;
- and tissue inflammation.
Proteomic studies have identified complement-associated abnormalities in Long COVID.
The potential interaction between complement and coagulation is particularly important because these systems are tightly coupled at the endothelial interface.
VIII. Monocyte Reprogramming
A major advance in 2025–26 has been the identification of a distinct circulating monocyte state associated with Long COVID.
Single-cell multi-omic analysis identified a population designated LC-Mo, characterized by:
- altered transcription;
- TGF-β signalling;
- WNT–β-catenin signalling;
- AP-1 and NF-κB-associated programmes;
- elevated inflammatory chemokines;
- impaired interferon responses.
The abundance of this monocyte phenotype correlated with fatigue and respiratory symptoms. Similar profibrotic macrophage programmes were observed in bronchoalveolar lavage specimens from patients with severe respiratory manifestations.
This finding is significant because it connects:
systemic immune dysregulation
with
organ-specific tissue pathology.
It also demonstrates that Long COVID can involve durable transcriptional reprogramming of immune cells rather than merely transient elevation of cytokines.
IX. T-Cell Dysfunction
T cells occupy a paradoxical position in Long COVID.
Some studies demonstrate evidence of persistent activation, whereas others demonstrate exhaustion or impaired cytotoxic function.
These findings are not necessarily contradictory.
Persistent antigen exposure can produce precisely this phenotype:
continued stimulation + inadequate resolution → activation followed by functional exhaustion.
Recent data showing reduced cytotoxic T-cell and granzyme-B signatures together with persistent inflammatory signalling support this interpretation.
Such immune dysfunction could also impair clearance of persistent viral reservoirs.
Thus a potentially self-reinforcing loop emerges:
incomplete viral clearance → persistent antigen → T-cell dysfunction → further incomplete clearance.
X. Autoimmunity
Autoimmunity represents another plausible mechanism.
SARS-CoV-2 can generate antibodies and T-cell responses that potentially cross-react with host proteins through molecular mimicry and other mechanisms. Persistent antigen exposure could perpetuate autoreactive lymphocyte activation.
The difficulty is that no single autoantibody profile defines Long COVID.
This suggests that autoimmunity probably represents one endotype rather than the universal mechanism.
Potential mechanisms include:
- molecular mimicry;
- epitope spreading;
- nonspecific B-cell activation;
- altered regulatory T-cell function;
- persistent antigen presentation;
- and tissue damage exposing previously concealed antigens.
The clinical implications could be substantial if future research identifies discrete autoantibody-defined subgroups.
XI. Epstein–Barr Virus and the Persistent Virome
SARS-CoV-2 does not infect humans in isolation.
The host carries a complex virome containing latent herpesviruses and other persistent viruses.
EBV is particularly important because it resides permanently within B cells and can transition between latent and lytic states.
Evidence has associated markers of EBV reactivation with particular Long-COVID phenotypes, especially fatigue and cognitive symptoms. Long-COVID immune studies have also demonstrated altered antibody responses to latent viruses.
The most useful conceptual model is not that EBV universally causes Long COVID, but that:
SARS-CoV-2 → immune disturbance → latent-virus reactivation → secondary immune amplification.
This may constitute a biological amplifier in a subset of patients.
XII. Host Genomics
Why do some individuals recover rapidly while others develop persistent disease?
Host genetics is likely part of the explanation.
The relevant genomic systems include:
- HLA antigen presentation;
- interferon signalling;
- innate viral sensing;
- B-cell activation;
- T-cell regulation;
- complement;
- cytokine signalling;
- and metabolic regulation.
Recent population-scale genomic work on EBV persistence provides an instructive precedent. Analysis of more than 735,000 individuals identified genetic determinants of persistent EBV DNA, with enrichment in immune regulatory regions and evidence implicating antigen presentation, B cells, antigen-presenting cells and HLA class II variation.
A similar architecture may influence susceptibility to persistent SARS-CoV-2 or to the immune consequences of infection.
The future of Long-COVID genomics should therefore integrate:
human genotype + viral genotype + immune phenotype + clinical phenotype.
XIII. Viral Evolution Within the Host
Persistent infection also creates an evolutionary problem.
In individuals unable to clear SARS-CoV-2, prolonged viral replication can permit accumulation of adaptive mutations, including mutations facilitating immune escape.
This phenomenon has been documented most clearly in severely immunocompromised patients.
Its relevance to ordinary Long COVID remains uncertain.
Nevertheless, it establishes an important biological principle:
the longer a virus persists under immune selection, the greater the opportunity for within-host evolution.
Future Long-COVID studies should therefore distinguish:
- residual nonreplicating RNA;
- persistent transcription;
- persistent replication;
- and genetically evolving viral populations.
These are biologically different states.
XIV. Endothelial Dysfunction and Microvascular Disease
The vascular system provides a plausible common pathway connecting disparate organ manifestations.
Endothelial activation can alter:
- vascular tone;
- platelet adhesion;
- coagulation;
- leukocyte trafficking;
- tissue oxygenation;
- and microvascular perfusion.
Evidence of complement and coagulation activation in Long COVID supports a model of persistent vascular inflammation.
The resulting physiology could be especially consequential in tissues with high metabolic demand.
The brain, myocardium and skeletal muscle are particularly vulnerable to impaired microvascular regulation.
XV. Autonomic Dysfunction
Dysautonomia is one of the most recognizable Long-COVID phenotypes.
Patients may develop:
- orthostatic tachycardia;
- orthostatic intolerance;
- abnormal blood-pressure regulation;
- temperature dysregulation;
- gastrointestinal dysmotility;
- sweating abnormalities;
- and exercise intolerance.
Several mechanisms are plausible:
- autonomic nerve injury;
- autoimmune dysfunction;
- endothelial abnormalities;
- impaired cerebral perfusion;
- altered baroreflex function;
- persistent inflammatory signalling.
The autonomic nervous system may consequently represent a final common physiological pathway rather than a single primary lesion.
XVI. Mitochondrial and Metabolic Dysfunction
Persistent fatigue has generated considerable interest in mitochondrial biology.
Recent proteomic analyses have identified abnormalities involving:
- amino-acid metabolism;
- metabolic signalling;
- leptin pathways;
- mitochondrial-associated metabolic processes;
- and DNA-repair pathways.
The physiological implication is potentially profound.
Skeletal muscle must increase ATP production dramatically during exercise.
If oxidative phosphorylation, substrate utilization, oxygen delivery or autonomic regulation is impaired, ordinary exertion may generate disproportionate physiological stress.
This could contribute to the characteristic phenomenon of:
post-exertional malaise.
Importantly, fatigue should therefore not be equated with subjective tiredness.
In some patients it may represent a disorder of systemic energy regulation.
XVII. Neurological Pathology
Neurological Long COVID encompasses:
- cognitive impairment;
- memory disturbance;
- attention deficits;
- headache;
- dizziness;
- altered smell and taste;
- neuropathic symptoms;
- sleep abnormalities;
- and autonomic dysfunction.
Potential mechanisms include:
- neuroinflammation;
- endothelial dysfunction;
- altered cerebral perfusion;
- blood–brain-barrier abnormalities;
- peripheral nerve dysfunction;
- immune-mediated injury;
- persistent antigen;
- and altered glial physiology.
The brain need not be directly infected by large quantities of virus to experience substantial dysfunction.
A systemic inflammatory or vascular disorder can produce neurological consequences without requiring widespread neuronal infection.
XVIII. Pulmonary Pathology
Pulmonary Long COVID is similarly heterogeneous.
Some patients demonstrate:
- persistent diffusion abnormalities;
- reduced exercise capacity;
- radiographic abnormalities;
- airway dysfunction;
- or evidence of interstitial injury.
The discovery of profibrotic monocyte/macrophage transcriptional programmes provides a mechanistic explanation for persistent pulmonary inflammation in at least some patients.
Importantly, the pulmonary phenotype differs according to the severity of the original infection.
Long COVID following severe pneumonia may represent persistent structural injury, whereas respiratory Long COVID after mild disease may arise from fundamentally different immunological mechanisms.
This distinction has major implications for treatment.
XIX. Gastrointestinal Disease and the Microbiome
The gastrointestinal tract is increasingly recognized as a potential reservoir and immunological interface.
Persistent SARS-CoV-2 material in gastrointestinal tissue could affect:
- mucosal immunity;
- epithelial integrity;
- intestinal permeability;
- microbial composition;
- and systemic immune signalling.
Microbiome disturbance may subsequently contribute to:
- altered immune regulation;
- metabolic abnormalities;
- gastrointestinal symptoms;
- and systemic inflammation.
The gastrointestinal tract may therefore function as both a viral reservoir and an immunological amplifier.
XX. Clinical Course
Long COVID does not follow one trajectory.
Three broad patterns can be recognized.
Persistent disease
Symptoms begin after acute infection and remain relatively continuous.
Relapsing–remitting disease
Patients experience periods of partial recovery followed by exacerbations.
Delayed-onset disease
The patient initially recovers and develops symptoms weeks or months later.
The third pattern is particularly important because it argues against a simplistic model in which ongoing symptoms are merely residual tissue damage from the original infection.
The clinical course may instead reflect delayed immune, metabolic or viral events.
XXI. Post-Exertional Malaise
Post-exertional malaise is among the most disabling manifestations.
Patients may experience disproportionate worsening after physical or cognitive exertion, sometimes delayed by many hours.
Possible mechanisms include:
- impaired metabolic flexibility;
- autonomic dysfunction;
- abnormal immune signalling;
- mitochondrial stress;
- altered skeletal-muscle physiology;
- endothelial dysfunction;
- and impaired oxygen utilization.
The phenomenon should not be dismissed as deconditioning.
Conversely, the presence of PEM does not establish any single molecular mechanism.
It is a clinical phenotype that requires physiological characterization.
XXII. Clinical Heterogeneity and Endotypes
The accumulated evidence increasingly supports the concept of Long COVID endotypes.
A useful conceptual classification might include:
Viral-persistence endotype
Persistent SARS-CoV-2 antigen or replication.
Immune-inflammatory endotype
Persistent cytokine, complement and immune activation.
Autoimmune endotype
Clinically relevant autoreactive antibodies or T-cell responses.
Vascular endotype
Endothelial, platelet and microvascular dysfunction.
Autonomic endotype
Orthostatic intolerance and dysautonomia.
Metabolic endotype
Abnormal energy metabolism and exercise physiology.
Neuroinflammatory endotype
Predominantly cognitive, sensory and neurological disease.
Most patients will probably occupy more than one category.
XXIII. Why a Single Treatment Is Unlikely to Work
The mechanistic heterogeneity explains a major therapeutic observation: no single treatment has yet produced consistent remission across unselected Long-COVID populations.
For example, a patient whose principal pathology is persistent antigen may theoretically benefit from antiviral therapy.
A patient whose dominant pathology is autoimmune may require immunomodulation.
A patient with autonomic dysfunction may require physiological and pharmacological autonomic treatment.
A patient with pulmonary fibrosis may require an entirely different strategy.
The failure of one treatment therefore does not necessarily falsify a mechanism.
It may simply demonstrate that the wrong biological subgroup was treated.
XXIV. The Therapeutic Experiment as the Test of Causality
The central scientific challenge is moving from association to causation.
For each proposed mechanism, the strongest evidence would be:
biomarker → temporal precedence → mechanistic plausibility → intervention → biological correction → clinical improvement.
For viral persistence:
persistent virus → antiviral therapy → viral clearance → symptom improvement.
For autoimmune disease:
pathogenic antibody → targeted immune intervention → antibody reduction → clinical improvement.
For dysautonomia:
objective physiological abnormality → targeted autonomic therapy → physiological normalization → functional improvement.
This framework should guide future clinical trials.
XXV. A Unified Pathophysiological Model
The evidence permits construction of a more comprehensive model.
Phase I — Acute infection
SARS-CoV-2 infects susceptible tissues and produces systemic inflammation.
Phase II — Failure of complete biological resolution
In some individuals, viral material persists, tissue injury remains, or immune homeostasis fails to return to baseline.
Phase III — Immune divergence
Persistent antigen and tissue injury generate chronic innate activation, altered T-cell function, B-cell perturbation and complement activation.
Phase IV — Secondary amplification
Latent-virus reactivation, autoimmunity, microbiome disturbance and metabolic stress amplify the inflammatory state.
Phase V — Organ dysfunction
Endothelial, autonomic, neurological, pulmonary, gastrointestinal and metabolic systems become functionally impaired.
Phase VI — Self-sustaining disease
The initiating virus may become less important than the pathological state it has created.
This last transition may explain why some patients remain symptomatic after conventional evidence of infection has disappeared.
XXVI. A Genomic–Immunological Model of Susceptibility
An important unresolved question is why only some infected individuals develop persistent disease.
A useful model is:
host genotype
×
viral genotype
×
initial viral burden
×
immune response
×
comorbid biology
×
sex/age/hormonal environment
×
vaccination and prior immunity
→
probability and phenotype of PASC.
This multiplicative framework better explains the heterogeneity than any single risk factor.
XXVII. What Is Established and What Remains Hypothesis?
Relatively well established
- Long COVID is a genuine multisystem postinfectious condition.
- It can occur after mild or severe acute infection.
- Immune abnormalities can persist for months.
- Complement and inflammatory pathways are altered in subsets.
- T-cell and myeloid abnormalities occur.
- Persistent SARS-CoV-2 material can be detected in some patients.
- Some patients exhibit latent-virus reactivation.
- Clinical phenotypes are highly heterogeneous.
Strongly plausible but incompletely proven
- Persistent SARS-CoV-2 reservoirs cause disease in a subset.
- EBV reactivation contributes causally to particular phenotypes.
- Autoantibodies are pathogenic in some patients.
- Microvascular dysfunction contributes to exercise and cognitive impairment.
- Metabolic dysfunction contributes to post-exertional malaise.
Not yet established
- A single universal cause of Long COVID.
- A single diagnostic biomarker.
- A universally effective antiviral treatment.
- That all patients with Long COVID have persistent virus.
- That all patients with Long COVID have EBV reactivation.
This distinction is essential for scientifically rigorous clinical practice.
XXVIII. Future Research Agenda
The next generation of Long-COVID studies should move beyond symptom questionnaires alone.
A definitive longitudinal study should integrate:
whole-genome sequencing
viral sequencing
single-cell transcriptomics
proteomics
metabolomics
immune-cell phenotyping
tissue virology
autonomic physiology
exercise physiology
digital longitudinal phenotyping.
Participants should be characterized from the acute infection onward rather than recruited only after chronic disease has developed.
The most important comparison is not simply:
Long COVID vs healthy controls.
It is:
acute infection → recovery versus acute infection → persistent disease.
That design permits identification of biological events that precede chronic illness.
Conclusion
Long COVID should now be regarded as a complex postviral multisystem disorder with multiple interacting biological mechanisms, rather than as a nonspecific collection of residual symptoms.
The strongest contemporary evidence supports a model in which SARS-CoV-2 infection can initiate persistent perturbation of the host through several convergent pathways: viral persistence, chronic inflammation, immune exhaustion, complement activation, altered monocyte and lymphocyte states, autoimmunity, endothelial dysfunction, autonomic disturbance, metabolic abnormalities and latent-virus reactivation.
The discovery of persistent SARS-CoV-2 RNA and protein in tissues has made viral persistence biologically credible; population surveillance has linked prolonged infection with increased risk of Long COVID.
The newer single-cell and multi-omic literature is equally important because it demonstrates that the host immune system itself can remain profoundly altered long after acute infection. Persistent IL-6/JAK–STAT activation, complement signalling, immune exhaustion and metabolic abnormalities suggest that the chronic phase is not simply a passive residue of the acute illness.
The identification of an LC-associated monocyte transcriptional state, including profibrotic and impaired-interferon programmes, further suggests that immune cells may undergo durable functional reprogramming capable of linking systemic inflammation to organ-specific pathology.
The most useful conceptual advance is consequently to abandon the search for the cause of Long COVID.
There may be several.
SARS-CoV-2 may initiate disease through a common inflammatory insult, after which individual biological susceptibilities determine the trajectory. In one patient the dominant mechanism may be persistent viral antigen; in another, autoimmune activation; in another, endothelial dysfunction; in another, dysautonomia or metabolic impairment; and in still another, a combination of these mechanisms amplified by reactivation of latent viruses.
Long COVID is therefore best understood as a network disease.
The initiating virus may disappear while the network it perturbed remains active.
The central challenge for the next phase of research is to identify the molecular state that sustains disease in each patient and to convert those states into biomarker-defined, mechanism-specific clinical trials.
Only then will Long COVID move from a syndrome recognized primarily through its symptoms to a set of diseases diagnosable and treatable through their underlying biology.
Numbered References
- Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nature Reviews Immunology. 2023;23:618–634.
- Ceglarek L, Boyman O. Immune dysregulation in long COVID. Nature Immunology. 2024;25:587–589.
- Klein J, Wood J, Jaycox JR, et al. Distinguishing features of Long COVID identified through immune profiling. Nature. 2023;623:139–148.
- Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881–895.
- Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21:133–146.
- Peluso MJ, Deveau TM, Munter SE, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. Journal of Clinical Investigation. 2023;133:e163669.
- Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein–Barr virus reactivation. Pathogens. 2021;10:763.
- Su Y, Chen D, Yuan D, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881–895.
- Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nature Immunology. 2022;23:210–216.
- Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated with multiple sclerosis. Science. 2022;375:296–301.
- Lanz TV, Brewer RC, Ho PP, et al. Clonally expanded B cells in multiple sclerosis bind to Epstein–Barr virus EBNA1 and GlialCAM. Nature. 2022;603:321–327.
- Sigal A, Neher RA, Lessells RJ. The consequences of SARS-CoV-2 within-host persistence. Nature Reviews Microbiology. 2025;23:288–302.
- Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758–766.
- Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute COVID-19 sequelae. Clinical Infectious Diseases. 2023;76:e487–e490.
- Craddock C, et al. Persistent SARS-CoV-2 RNA in tissues and its potential relationship to post-acute sequelae. The tissue-reservoir literature is reviewed in the context of PASC by Altmann and colleagues.
- Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nature Medicine. 2022;28:2398–2405.
- Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine. 2022;28:1461–1467.
- Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.
- Pretorius E, Venter C, Laubscher GJ, et al. Persistent clotting protein pathology in Long COVID/post-acute sequelae of COVID-19. Cardiovascular Diabetology. 2021;20:172.
- Aid M, Boero-Teyssier V, McMahan K, et al. Long COVID involves activation of proinflammatory and immune exhaustion pathways. Nature Immunology. 2026;27:61–71. This longitudinal immunological, virological, transcriptomic and proteomic study found persistent inflammatory, complement, metabolic and immune-exhaustion signatures beyond 180 days.
- [Authors]. A distinct monocyte transcriptional state links systemic immune dysregulation to pulmonary impairment in long COVID. Nature Immunology. 2026. The study identified the LC-Mo state, associated with fatigue, respiratory symptoms, TGF-β/WNT signalling, profibrotic programmes and impaired interferon responses.
- [Authors]. Immunologically distinct long COVID after mild acute disease. Nature Immunology. 2026;27:173–174. The work highlights distinct immune programmes after mild-to-moderate versus severe acute COVID-19.
- [Authors]. Prevalence of persistent SARS-CoV-2 in a large community surveillance study. Nature. 2024. Persistent high-titre infection was associated with increased odds of Long COVID.
- [Authors]. Population-scale sequencing resolves determinants of persistent EBV DNA. Nature. 2026. Whole-genome analyses involving more than 735,000 participants implicated immune regulatory loci, B cells, antigen-presenting cells and HLA class II variation in persistent EBV DNA.
- Current evidence concerning Long-COVID pathogenesis supports a heterogeneous, interacting network of viral persistence, immune dysregulation, autoimmunity, endothelial dysfunction, metabolic disturbance and latent-virus reactivation rather than a single mechanism.